JY
APGE icon

Jeff Yass’s Apogee Therapeutics APGE Stock Holding History

Jeff Yass’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.62M Buy
27,256
+11,157
+69% +$1.01M ﹤0.01% 5240
2026
Q1 		$1.36M Buy
16,099
+11,465
+247% +$833K ﹤0.01% 7143
2025
Q4 		$350K Sell
4,634
-12,055
-72% -$759K ﹤0.01% 9588
2025
Q3 		$663K Sell
16,689
-22,008
-57% -$840K ﹤0.01% 8336
2025
Q2 		$1.68M Sell
38,697
-31,641
-45% -$1.2M ﹤0.01% 6170
2025
Q1 		$2.63M Buy
70,338
+39,050
+125% +$1.51M ﹤0.01% 4935
2024
Q4 		$1.42M Sell
31,288
-20,242
-39% -$1.03M ﹤0.01% 6090
2024
Q3 		$3.03M Buy
51,530
+36,407
+241% +$1.74M ﹤0.01% 4523
2024
Q2 		$595K Sell
15,123
-1,535
-9% -$74.5K ﹤0.01% 7851
2024
Q1 		$1.11M Buy
16,658
+7,177
+76% +$313K ﹤0.01% 6647
2023
Q4 		$265K Buy
+9,481
New +$190K ﹤0.01% 10087

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Jeff Yass's APGE Position: Q2 2026 in Review

Jeff Yass increased its Apogee Therapeutics (APGE) stake by 69% in Q2 2026, buying an estimated $1.01M and bringing the position to 27,256 shares worth $3.62M. The position accounts for ﹤0.01% of the portfolio, ranked #5240.

Jeff Yass first reported a position in APGE in Q4 2023 and has held it in 11 quarters since. 286 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Jeff Yass held 27,256 shares of Apogee Therapeutics worth $3.62M as of Q2 2026.
  • Jeff Yass bought 11,157 Apogee Therapeutics shares in Q2 2026, an estimated $1.01M.
  • Apogee Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5240 holding.
  • Jeff Yass first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 286 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.